Heterocyclic Arylidene Chemical Compounds vs. Glioblastoma
Overview
Glioblastoma multiforme (GBM) is a very deadly form of brain cancer. The effects of hybrid compounds of heterocyclic rhodanine and arylidene (boronic acid) were tested on GBM cancer cells. The cells were grown in 96 well culture plates and treated with four different concentrations. Since both drugs had anti-cancer properties, the hybrid had a high probability of killing a large amount of cells. The goal was to kill as many cells as possible with the lowest concentration possible. The compound of rhodanine-4-formyl-phenyl boronic acid (J MCL 1) showed a large decrease in cell count, while rhodanine-paraformaldehyde (J MCL 4) showed significant decrease with the 2.0 mg/mL concentration. The results proved that the highest concentration was most effective. It was concluded that bonds in para-position on the benzene ring cause a significant effect on cell count.
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2026
Development of Peptide-Drug Conjugates Targeting Glioblastoma Cells
ISEF · 2023
Sulforaphane and Panobinostat: A Novel Therapy for Glioblastoma Multiforme
AJAS · 2018
Synthesis of Boron-Based Natural Products as Anti-Cancer Agents
AJAS · 2020
Targeting the Nf-Kb and Mgmt Pathways in Newly Diagnosed Glioblastoma
AJAS · 2017
Combinatorial Effects of Bitter Melon and Temozolomide on Glioma Cells
CSEF · 2014
Inhibition of Jak2 and PKC Induces Synergistic Apoptosis in Glioblastoma
ISEF · 2017
Inhibiting the Proliferation of Patient-Derived Glioblastoma Multiforme (GBM) Cells and U-87 MG Cell Line Using Leaf Extract of Bacopa monnieri
AJAS · 2020
Identification of Inhibitors of Glioblastoma Stem Cells by High-Throughput Screening
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair